Authors
Latest:
Avoiding a CIA: Analytics and the Search for Dangerous DataInternal oversight and the tools to remain compliant are critical to companies seeking to avoid corporate integrity agreements (CIAs) or efficiently fulfill existing agreements. In either case, CIAs can be a business advantage, writes Gabriela P. Baron.
Latest:
mAb Biosimilars: The Future of Cancer Treatment?Time will determine the shape of biosimilar usage in oncology, but they will play a significant role in the battle against cancer in the future, writes Alessandra Franceschetti.
Latest:
Beyond the Science: Commercial Implications From ASCO 2017Four strategic takeaways from this year's that are important for pharma oncology leaders.
Latest:
The Future of Real-World StudiesPharma companies today must increasingly provide evidence on real-world outcomes to differentiate and justify their products. But what is the true potential of real-world evidence studies and what are the right questions to ask in determining product performance in the marketplace?
Latest:
How Emerging Biopharmas Can Obtain VC FundingKen Shimokawa, Founder and General Partner of G4S Capital, shares insights into what venture capitalists look for when evaluating emerging biopharmaceutical opportunities.
Latest:
Aligning Early Advice with Long-Term PlanningThe five ways pharma developers can get the most out of early engagement with payers and regulators when plotting their clinical and commercial evidence plans.
Latest:
Time to Disrupt SOPsPharma companies still keep thousands of manufacturing procedures as text documents, an inefficient method can lead to defective batches, recalls and warning letters. Why not use video for training where applicable, asks Boaz Sigelman.
Latest:
Packaging for Patient EngagementFunso Olufade discusses how solutions such as the new Adherence Package can help increase pharma–patient engagement.
Latest:
Financial Toxicity: Tracking a Growing Side EffectJeremy Schafer and Deborah Lotterman discuss the impact that financial toxicity is having on patients and payers and outline the strategies pharma need to adopt to begin to remedy it.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Functional Service Partnerships: A Case Study for CRO Resource ManagementA review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
Latest:
Key Regulatory Deadlines Loom for Drug Dispensers and WholesalersThe COVID-19 pandemic is currently top of mind among pharma professionals, but stakeholders have other business to attend to – such as the upcoming deadline to meet regulatory requirements of the US FDA’s 2013 Drug Supply Chain Security Act.
Latest:
AI & Lab Data: Enabling Decision-Making in Real TimeLisa Kerber outlines how the pharma industry can take advantage of combining new clinical data sources such as diagnostics, or lab data, with AI to deliver on the promise of improving outcomes.
Latest:
Can A New Value Framework Help Ease Friction Over Orphan Drug Prices?Even on the contentious topic of orphan drug pricing, the last few months have brought hopeful signs that patients, pharmaceutical companies, health insurers, and the academic bodies that counsel them are trying to speak the same language.
Latest:
mHealth: Changing the Dynamics of the Healthcare EcosystemmHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.
Latest:
Why Your Advertising Agency Should Be Your Analytics PartnerBrands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.
Latest:
Navigating the Untapped NASH MarketA potential rush of treatment options on the horizon for non-alcoholic steatohepatitis will require skillful maneuvering in this likely lucrative but uncharted therapeutic market.
Latest:
The Rising Tide of Next Generation Cancer TreatmentsThe Ipsos Healthcare Oncology Centre of Excellence's Jackie Ilacqua & Valerie Wriede trace the evolution of cancer treatment and drill down into the latest developments currently redefining the landscape, together with those on the horizon.
Latest:
NASH: Pointers for Pharma from the Patient PerspectiveWith the NASH pipeline filling up fast, Mariel Metcalfe looks at what pharma companies need to do to ensure their products do not end up as also-rans in this dynamic new market segment.
